Celldex Q4 Earnings Miss Expectations
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Should l Buy CLDX?
Source: seekingalpha
- Disappointing Earnings: Celldex reported a Q4 GAAP EPS of -$1.22, missing expectations by $0.20, indicating ongoing challenges in profitability that may affect investor confidence.
- Significant Revenue Decline: The company generated only $0.12M in revenue for Q4, a staggering 89.8% year-over-year drop, falling short of the anticipated $1.34M, reflecting a notable weakness in product sales that could increase future cash flow pressures.
- Decreased Cash Reserves: As of December 31, 2025, Celldex's cash, cash equivalents, and marketable securities totaled $518.6M, down from $583.2M as of September 30, 2025, highlighting challenges in cash management that may impact its R&D and operational capabilities.
- Clinical Trial Progress: Despite the poor financial performance, Celldex has completed enrollments in late-stage trials for its lead asset, potentially paving the way for future product launches, although short-term financial pressures remain.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLDX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLDX
Wall Street analysts forecast CLDX stock price to rise
10 Analyst Rating
9 Buy
0 Hold
1 Sell
Strong Buy
Current: 34.550
Low
24.00
Averages
55.00
High
90.00
Current: 34.550
Low
24.00
Averages
55.00
High
90.00
About CLDX
Celldex Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on exploring the science of mast cell biology and the development of transformative therapeutics for patients. Its pipeline includes antibody-based therapeutics which have the ability to engage the human immune system and/or directly affect critical pathways to improve the lives of patients with severe inflammatory, allergic, autoimmune and other devastating diseases. Its drug candidates include monoclonal and bispecific antibodies designed to address mast cell mediated diseases. Its Barzolvolimab (CDX-0159) is a monoclonal antibody that specifically binds the KIT receptor and potently inhibits its activity, which is being studied across multiple mast cell driven diseases, including Chronic Urticarias, Prurigo Nodularis, Atopic Dermatitis and Eosinophilic Esophagitis. The Company’s bispecific platform includes CDX- 622. The CDX- 622 is a bispecific candidate for inflammatory diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Major Wall Street Rating Updates on Monday
- Tesla Rating Adjustment: Jefferies raised Tesla's price target from $300 to $350, anticipating Q1 results will show a widening gap between vision and execution, and concerns about funding may arise without a convincing robotaxi announcement, potentially leading to merger considerations with SpaceX.
- Apple's Positive Outlook: Morgan Stanley reiterated Apple as overweight, expecting a modest 1-2% upside in revenue and EPS in the upcoming earnings report, despite supply constraints, indicating the company's resilience in the market.
- Amazon Price Target Increase: Bank of America raised Amazon's price target from $275 to $298, believing that with strong assets and customer focus, Amazon is well-positioned to capitalize on the global growth of eCommerce and enterprise demand for AI capabilities, showcasing robust growth potential.
- Microsoft's Favorable Outlook: Deutsche Bank reiterated Microsoft as a buy, expecting Azure's performance and guidance to be focal points in the upcoming earnings report, indicating that the company's broad progress in AI initiatives will drive future growth.
See More
Celldex Closes $345 Million Public Offering of 11.9 Million Shares
- Offering Size: Celldex Therapeutics successfully closed its public offering of 11,896,750 shares of common stock, which included the full exercise of the underwriters' option to purchase an additional 1,551,750 shares at a public offering price of $29.00 per share, indicating strong market demand for its stock.
- Funding Amount: The offering generated approximately $345 million in gross proceeds for Celldex, excluding underwriting discounts and other related expenses, with the funds earmarked to advance its biotechnology research projects, thereby enhancing the company's competitive edge in the clinical stage.
- Underwriter Lineup: The offering was managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor as joint bookrunning managers, with LifeSci Capital and H.C. Wainwright & Co. serving as co-lead managers, reflecting robust market support for the transaction.
- Registration Statement: The securities were offered under a shelf registration statement on Form S-3 filed with the SEC, demonstrating Celldex's commitment to compliance and laying the groundwork for future financing activities.
See More
Celldex Therapeutics Prices $300M Public Offering for Pipeline Expansion
- Public Offering Pricing: Celldex Therapeutics has priced an underwritten public offering of approximately 10.3 million shares at $29.00 per share, expecting gross proceeds of about $300 million, which underscores the company's ability to raise capital in the market.
- Additional Share Option: The underwriters have a 30-day option to purchase up to an additional 1.55 million shares, providing the company with flexibility for further financing and potentially enhancing market confidence.
- Clear Use of Proceeds: The funds raised will support the commercial readiness and potential U.S. launch of barzolvolimab for chronic spontaneous urticaria, if approved, alongside clinical and preclinical development of product candidates, indicating the company's focus on new product initiatives.
- Stock Price Fluctuation: Following the public offering announcement, Celldex's stock price dropped about 3.5% during pre-market trading on Thursday, reflecting a cautious market reaction to the financing news, which may impact investor confidence.
See More
Celldex Therapeutics Prices Public Offering at $29 per Share
- Public Offering Pricing: Celldex Therapeutics has priced its public offering of 10.345 million shares at $29 each, expecting gross proceeds of $300 million, although the stock fell 3.45% in after-hours trading to $30.18, indicating cautious market sentiment towards the offering.
- Use of Proceeds: The net proceeds from this offering will be combined with existing cash and equivalents to fund ongoing commercial readiness and the potential launch of Barzolvolimab, if approved, while also supporting preclinical development of product candidates, demonstrating the company's commitment to drug development.
- Financial Condition Analysis: Celldex anticipates a wider net loss of $258.76 million for 2025, translating to a loss of $3.90 per share, compared to a loss of $157.86 million the previous year, reflecting high costs associated with R&D and market promotion.
- Declining Revenue Trend: The company's total revenue has decreased from $7.02 million in the prior year to $1.55 million, primarily due to reduced services under agreements with Rockefeller University, indicating challenges in revenue diversification.
See More
Celldex Announces Public Offering of Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, indicating the company's focus on reputable underwriters to ensure successful capital raising and market impact.
- Use of Proceeds: Celldex intends to utilize the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, thereby enhancing its product pipeline and competitive positioning.
- Compliance and Transparency: The offering is conducted under SEC's S-3 registration statement, ensuring compliance and transparency, which further builds investor trust in the company's governance and financial health.
See More
Celldex Therapeutics Prices Public Offering of 10.3 Million Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at a price of $29.00 per share, expecting to raise approximately $300 million in gross proceeds, which will significantly enhance the company's financial strength to support future R&D and commercialization activities.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, reflecting strong market confidence in Celldex while providing robust capital market support for the company.
- Planned Use of Proceeds: Celldex intends to use the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, indicating the company's proactive strategy in drug development and market entry.
- Compliance and Transparency: The offering is made under a previously filed S-3 registration statement, ensuring compliance and transparency, which further enhances investor trust in Celldex and lays a solid foundation for future capital operations.
See More
Major Wall Street Rating Updates on Monday
- Tesla Rating Adjustment: Jefferies raised Tesla's price target from $300 to $350, anticipating Q1 results will show a widening gap between vision and execution, and concerns about funding may arise without a convincing robotaxi announcement, potentially leading to merger considerations with SpaceX.
- Apple's Positive Outlook: Morgan Stanley reiterated Apple as overweight, expecting a modest 1-2% upside in revenue and EPS in the upcoming earnings report, despite supply constraints, indicating the company's resilience in the market.
- Amazon Price Target Increase: Bank of America raised Amazon's price target from $275 to $298, believing that with strong assets and customer focus, Amazon is well-positioned to capitalize on the global growth of eCommerce and enterprise demand for AI capabilities, showcasing robust growth potential.
- Microsoft's Favorable Outlook: Deutsche Bank reiterated Microsoft as a buy, expecting Azure's performance and guidance to be focal points in the upcoming earnings report, indicating that the company's broad progress in AI initiatives will drive future growth.
See More
Celldex Closes $345 Million Public Offering of 11.9 Million Shares
- Offering Size: Celldex Therapeutics successfully closed its public offering of 11,896,750 shares of common stock, which included the full exercise of the underwriters' option to purchase an additional 1,551,750 shares at a public offering price of $29.00 per share, indicating strong market demand for its stock.
- Funding Amount: The offering generated approximately $345 million in gross proceeds for Celldex, excluding underwriting discounts and other related expenses, with the funds earmarked to advance its biotechnology research projects, thereby enhancing the company's competitive edge in the clinical stage.
- Underwriter Lineup: The offering was managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor as joint bookrunning managers, with LifeSci Capital and H.C. Wainwright & Co. serving as co-lead managers, reflecting robust market support for the transaction.
- Registration Statement: The securities were offered under a shelf registration statement on Form S-3 filed with the SEC, demonstrating Celldex's commitment to compliance and laying the groundwork for future financing activities.
See More
Celldex Therapeutics Prices $300M Public Offering for Pipeline Expansion
- Public Offering Pricing: Celldex Therapeutics has priced an underwritten public offering of approximately 10.3 million shares at $29.00 per share, expecting gross proceeds of about $300 million, which underscores the company's ability to raise capital in the market.
- Additional Share Option: The underwriters have a 30-day option to purchase up to an additional 1.55 million shares, providing the company with flexibility for further financing and potentially enhancing market confidence.
- Clear Use of Proceeds: The funds raised will support the commercial readiness and potential U.S. launch of barzolvolimab for chronic spontaneous urticaria, if approved, alongside clinical and preclinical development of product candidates, indicating the company's focus on new product initiatives.
- Stock Price Fluctuation: Following the public offering announcement, Celldex's stock price dropped about 3.5% during pre-market trading on Thursday, reflecting a cautious market reaction to the financing news, which may impact investor confidence.
See More
Celldex Therapeutics Prices Public Offering at $29 per Share
- Public Offering Pricing: Celldex Therapeutics has priced its public offering of 10.345 million shares at $29 each, expecting gross proceeds of $300 million, although the stock fell 3.45% in after-hours trading to $30.18, indicating cautious market sentiment towards the offering.
- Use of Proceeds: The net proceeds from this offering will be combined with existing cash and equivalents to fund ongoing commercial readiness and the potential launch of Barzolvolimab, if approved, while also supporting preclinical development of product candidates, demonstrating the company's commitment to drug development.
- Financial Condition Analysis: Celldex anticipates a wider net loss of $258.76 million for 2025, translating to a loss of $3.90 per share, compared to a loss of $157.86 million the previous year, reflecting high costs associated with R&D and market promotion.
- Declining Revenue Trend: The company's total revenue has decreased from $7.02 million in the prior year to $1.55 million, primarily due to reduced services under agreements with Rockefeller University, indicating challenges in revenue diversification.
See More
Celldex Announces Public Offering of Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at $29.00 per share, expected to raise approximately $300 million, reflecting strong market demand and investor confidence in the company.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, indicating the company's focus on reputable underwriters to ensure successful capital raising and market impact.
- Use of Proceeds: Celldex intends to utilize the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, thereby enhancing its product pipeline and competitive positioning.
- Compliance and Transparency: The offering is conducted under SEC's S-3 registration statement, ensuring compliance and transparency, which further builds investor trust in the company's governance and financial health.
See More
Celldex Therapeutics Prices Public Offering of 10.3 Million Shares
- Offering Size: Celldex Therapeutics announced a public offering of 10,345,000 shares at a price of $29.00 per share, expecting to raise approximately $300 million in gross proceeds, which will significantly enhance the company's financial strength to support future R&D and commercialization activities.
- Underwriter Selection: The offering is managed by Leerink Partners, TD Cowen, Guggenheim Securities, and Cantor, reflecting strong market confidence in Celldex while providing robust capital market support for the company.
- Planned Use of Proceeds: Celldex intends to use the net proceeds from this offering to fund commercial readiness and launch of barzolvolimab, along with ongoing clinical and preclinical development, indicating the company's proactive strategy in drug development and market entry.
- Compliance and Transparency: The offering is made under a previously filed S-3 registration statement, ensuring compliance and transparency, which further enhances investor trust in Celldex and lays a solid foundation for future capital operations.
See More
